Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End
Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.
You may also be interested in...
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
US cost watchdog ICER has released its cost models for remdesivir, and says it wants to stimulate debate on how it and other COVID-19 therapies should be priced. Plus news from Amgen and ILC Therapeutics.
Relatively upbeat during the company’s Q1 call based on Amgen’s product mix, executives expect the biggest coronavirus-related sales impacts in Q2 with stabilization and growth in the second half.